Medicines for All Institute

What Medicines for All Institute does

Medicines for All Institute (M4ALL) is a research institute operating within the Virginia Commonwealth University College of Engineering in Richmond, Virginia, founded in 2017 with an initial $25 million grant from the Bill & Melinda Gates Foundation. Its core function is developing novel, low-cost synthetic routes and optimized manufacturing processes for active pharmaceutical ingredients (APIs) used in essential medicines for HIV, tuberculosis, malaria, COVID-19, and neglected tropical diseases. M4ALL has publicly documented process improvements for 22 drugs, with quantified raw-material cost reductions ranging from 10% to 90% depending on the molecule, and reports that 90% of HIV/AIDS patients globally use treatments developed through its processes.

The institute's technical platform combines novel synthetic chemistry with process intensification principles — including vertical integration of advanced starting materials from commodity chemicals, consolidation of high-yielding reactions into minimal unit operations, and alternative manufacturing platforms such as continuous flow reactors (Synthetron, spinning disk reactor, Vapourtec E-Series), continuous crystallization, and semi-continuous processing. Specific technical capabilities include telescoped palladium-catalyzed Heck-Suzuki coupling for lenacapavir, asymmetric synthesis using chiral transfer reagents for bedaquiline, and techno-economic cost analysis methodologies to identify cost drivers in existing commercial processes.

M4ALL operates an open-access technology transfer model: improved synthetic routes are published in peer-reviewed journals (OPRD, ACS, Angewandte Chemie) and process development reports are made available without licensing fees, enabling global pharmaceutical manufacturers to adopt the technologies. Total disclosed funding is $70 million from the Bill & Melinda Gates Foundation, US Government, and other donors. The institute is the technical anchor of the Richmond-Petersburg advanced pharmaceutical manufacturing cluster alongside Phlow Corp, Civica Rx, AMPAC Fine Chemicals, and Alliance for Building Better Medicine partners.

Name

Medicines for All Institute

Legal name

Medicines for All Institute

Website

https://medicines4all.vcu.edu

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Medicines for All Institute (M4ALL) is a VCU-based research institute that develops novel, low-cost synthetic routes for APIs in essential global health medicines (HIV, TB, malaria, COVID-19, NTDs), transferring improved processes open-access to pharmaceutical manufacturers worldwide.

Ownership category

akta.pro rank

Product category

Pharmaceutical Process Development Services

NAICS

Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Process Development & Route Scouting (HLAGAHAA)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• API process development
• Pharmaceutical manufacturing services
• Green chemistry synthesis
• Continuous flow chemistry
• Global health medicines

Headquarters

HQ city

Richmond

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Bill & Melinda Gates Foundation Funding: Primary funding source from the Bill & Melinda Gates Foundation to support process optimization for global health medicines targeting HIV, TB, malaria, and COVID-19. M4ALL was founded in 2017 with initial $25 million Gates Foundation grant.
2. US Government and Other Donor Funding: Funding from US Government sources and other donors. Total funding of $70 million from Gates Foundation, USG, and other donors.
3. Technology Transfer and Process Licensing: M4ALL transfers its improved technologies to pharmaceutical manufacturers at no cost through open-access publications and process development reports, enabling manufacturers to produce medicines at lower cost. Revenue comes from enabling cost reductions rather than direct licensing fees.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

The Medicines for All Institute (M4ALL) develops optimized synthetic routes and manufacturing processes for active pharmaceutical ingredients (APIs) used in essential medicines targeting HIV, tuberculosis, malaria, COVID-19, and neglected tropical diseases. The institute combines novel synthetic chemistry with process intensification, continuous flow processing, and green chemistry principles to reduce API manufacturing costs by 15-90%. M4ALL transfers its improved process technologies to pharmaceutical manufacturers worldwide at no cost through open-access publications, process development reports, and direct technology transfer partnerships.

Product overview

Medicines for All Institute (M4ALL) is a research institute within Virginia Commonwealth University's College of Engineering that provides process development services to reduce the cost of active pharmaceutical ingredient (API) manufacturing. The institute develops and optimizes synthetic routes for generic medications targeting global health diseases. Its core offering consists of process improvement services across multiple therapeutic areas: HIV (Nevirapine, Dolutegravir, Emtricitabine, Tenofovir, Lamivudine, Lenacapavir), COVID-19 (Remdesivir, Molnupiravir, Nirmatrelvir), Tuberculosis (Bedaquiline, Pretomanid, Sutezolid, OPC-167832, TBAJ-876), Malaria (MMV693183, Pyronaridine, Ganaplacide), and Visceral Leishmaniasis (DNDI-6148). The institute also provides pharmaceutical reshoring consultation services and workforce training programs. M4ALL's methodology combines novel chemistry with process intensification techniques including vertical integration of advanced starting materials, consolidation of high-yielding reactions, and evaluation of alternative manufacturing platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• HIV Drug Process Portfolio Improved synthesis processes for HIV antiretroviral medications including Nevirapine, Emtricitabine, Dolutegravir, Tenofovir (TDF/TAF), Lamivudine, and Lenacapavir. Provided to pharmaceutical manufacturers via open-access technology transfer to enable lower-cost generic API production.
• COVID-19 Drug Process Portfolio Improved synthesis processes for COVID-19 treatments including Remdesivir, Molnupiravir, and Nirmatrelvir (Paxlovid component). Includes process improvements such as yield doubling for Remdesivir triazine intermediate (33% to 59%) and yield improvement for Molnupiravir synthesis (17% to 61%).
• Tuberculosis Drug Process Portfolio Improved synthesis processes for tuberculosis medications including Bedaquiline, Pretomanid, Sutezolid, OPC-167832, and TBAJ-876. Achieves 15-66% raw material cost reduction for Bedaquiline, 45-55% for Sutezolid, and 10-20% for TBAJ-876, supporting accessibility for TB patients worldwide.
• Malaria Drug Process Portfolio Improved synthesis processes for malaria treatments including MMV693183, Pyronaridine (in partnership with PHT International), and Ganaplacide. Achieves 15-25% raw material cost reduction for Ganaplacide API and supports affordable production of next-generation antimalarials addressing artemisinin resistance.
• Neglected Tropical Disease Drug Process Portfolio Improved synthesis processes for neglected tropical disease treatments including DNDI-6148 for visceral leishmaniasis, developed in partnership with the Drugs for Neglected Diseases initiative (DNDi). Achieves up to 80-90% raw material cost reductions through route scouting.
• Pharmaceutical Reshoring Strategic Planning Strategic planning and collaborative services to reshore essential medicine production to the United States, reducing dependence on offshore production and securing domestic pharmaceutical supply chains. Includes cluster development work in the Richmond-Petersburg region.
• Workforce Training and Educational Programs Educational programs training scientists in advanced chemistry techniques and use of state-of-the-art facilities, developing the next generation of pharmaceutical manufacturing experts. Includes partnerships with VCU School of Pharmacy, VCU Chemistry Department, and Virginia State University.

Quantifiable outcome

• 15-25% raw material cost reduction for Ganaplacide API
• +14 more outcomes

Named customers8 records

Segments7 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

23 partnerships are on record, tiered core, major, regional and supporting.

• Phlow CorpcoreStrategic or Co-development PartnerRichmond-based pharmaceutical company leading a multiyear effort with M4ALL, AMPAC Fine Chemicals, and Civica Rx to create a supply and national stockpile of active pharmaceutical ingredients for essential medicines and develop new continuous processing manufacturing capability.
• Civica RxcoreStrategic or Co-development PartnerNon-profit pharmaceutical company collaborating with M4ALL and Phlow Corp to address critical drug shortages and create domestic pharmaceutical manufacturing capacity for essential medicines.
• AMPAC Fine ChemicalscoreStrategic or Co-development PartnerPetersburg-based pharmaceutical manufacturer part of the advanced pharmaceutical manufacturing cluster with M4ALL and Phlow Corp. Announced $25 million expansion investment in 2021 adding 156 new jobs.
• TB AlliancecoreStrategic or Co-development PartnerPartnership for developing lower-cost manufacturing processes for TB drugs including bedaquiline, pretomanid, sutezolid, OPC-167832, and TBAJ-876. M4ALL works with TB Alliance to ensure accessibility for TB patients worldwide.
• PHT InternationalmajorStrategic or Co-development PartnerPartnership for improved manufacturing process of pyronaridine tetraphosphate (antimalarial) at commercial scale. PHT executed process research, development, and scale-up work toward an improved manufacturing process.
• CRAMSNmajorStrategic or Co-development PartnerPartnership for scale-up of TBAJ-876 intermediate (876A-B) manufacturing process. CRAMSN received technology transfer and scaled up to 4 kg, demonstrating the process for TB drug accessibility.
• DNDi (Drugs for Neglected Diseases initiative)majorStrategic or Co-development PartnerPartnership for developing low-cost synthetic strategies for DNDI-6148, a visceral leishmaniasis drug candidate. M4ALL demonstrated 80-90% raw material cost reductions through route scouting.
• Medicines Patent PoolmajorStrategic or Co-development PartnerMemorandum of Understanding signed to improve access to lifesaving medicines through shared intellectual property and technology transfer.
• South African ManufacturerregionalStrategic or Co-development PartnerPartnership announced February 2020 to improve access to lifesaving medications in South Africa through technology transfer and manufacturing support.
• Ivory Coast GovernmentregionalStrategic or Co-development PartnerPartnership with Ivory Coast government announced November 2018 to improve access to lifesaving medicines through local manufacturing capabilities.
• Alliance for Building Better MedicinecoreStrategic or Co-development PartnerRegional collaboration part of the Richmond-Petersburg advanced pharmaceutical manufacturing cluster. Won the National Build Back Better Regional Challenge in September 2022.
• Virginia Center for Advanced Pharmaceutical ManufacturingcoreStrategic or Co-development PartnerWorkforce training partnership with Virginia institutions. AstraZeneca, Eli Lilly, and Merck committed $120 million toward developing this center as part of $12.5 billion pharmaceutical investment in Virginia.
• MITsupportingTechnology or IntegrationAcademic affiliate providing research collaboration and expertise in advanced pharmaceutical manufacturing.
• Georgia TechsupportingTechnology or IntegrationAcademic affiliate providing expertise in green chemistry and process development for global health drugs.
• University of GrazsupportingTechnology or IntegrationAcademic affiliate providing expertise in continuous processing and flow chemistry.
• University of MainzsupportingTechnology or IntegrationAcademic affiliate providing research collaboration in pharmaceutical process development.
• Mississippi State UniversitysupportingTechnology or IntegrationAcademic affiliate contributing to M4ALL's collaborative network.
• MarqmetrixsupportingTechnology or IntegrationTechnology partner providing process analytical technology (PAT) solutions for real-time monitoring of pharmaceutical processes.
• Virginia Commonwealth University College of EngineeringcoreOthersParent institution hosting M4ALL. Provides facilities, faculty, students, and academic infrastructure for research operations.
• Virginia Commonwealth University Chemistry DepartmentcoreOthersAcademic collaboration providing students opportunity to apply knowledge to real-world pharmaceutical engineering applications.
• VCU School of PharmacycoreOthersAcademic collaboration advancing pharmaceutical engineering and drug development education.
• Virginia State UniversitysupportingOthersPartner in science and engineering programs contributing to workforce development for the advanced pharmaceutical manufacturing cluster.
• AAP Pharma TechnologiesmajorStrategic or Co-development PartnerPartner in pretomanid API synthesis development, successfully demonstrating 1 kg scale synthesis with improved impurity profile.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cambrex: Global CDMO specializing in small-molecule API process development and manufacturing. Comparable to M4ALL in delivering route scouting, process optimization, and scale-up for pharmaceutical customers across therapeutic areas.
• Sai Life Sciences: CRO/CDMO providing API process development, scale-up, and manufacturing for global pharma. Comparable to M4ALL's mission of cost-effective API route development and tech transfer to generic and innovator manufacturers.
• Piramal Pharma Solutions: CDMO with strong small-molecule API development and high-potency capabilities. Direct peer in process chemistry services and technology transfer to pharma manufacturers.
• AMPAC Fine Chemicals: Custom API manufacturer and partner of M4ALL within the Richmond-Petersburg cluster. Comparable in custom small-molecule API process development and manufacture, and a direct collaboration partner on tech transfer.
• Pharmaron: Integrated CRO/CDMO with strong process chemistry and API development services. Comparable to M4ALL in providing route scouting, process optimization, and tech transfer to global pharma customers.
• Novasep: CDMO focused on API process development, purification, and manufacturing for pharma. Comparable in offering route development and scale-up services for small-molecule APIs across therapeutic areas.

Broad incumbents

• Lonza: One of the world's largest CDMOs offering small-molecule API development and manufacturing. Compares to M4ALL on process chemistry and API tech transfer, though Lonza operates at significantly greater scale and with a commercial (for-profit) model.
• WuXi STA (WuXi AppTec): Large global CDMO offering API process R&D and manufacturing. Comparable to M4ALL on small-molecule API route development, though at substantially greater commercial scale and with for-profit economics.

Emerging players

• Codexis: Developer of engineered enzymes and biocatalysis for API manufacturing. Comparable to M4ALL in applying novel process technologies (in Codexis's case biocatalysis, in M4ALL's case flow chemistry and process intensification) to reduce cost of complex small-molecule APIs.

Others

• Medicines Patent Pool: UN-backed public health organization that negotiates IP licenses to expand generic access to medicines. M4ALL has signed an MOU with MPP, and the two organizations are complementary in lowering barriers to global medicine access through different mechanisms (IP licensing vs. process technology transfer).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/virginia-commonwealth-university

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicines for All Institute